Joyce Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9813915/publications.pdf

Version: 2024-02-01

54911 61984 9,873 94 43 84 citations h-index g-index papers 97 97 97 6895 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the <i>MUC5B</i> Promoter Variant. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 473-476.	5.6	12
2	FocuSSced on the Target in Systemic Sclerosis–Interstitial Lung Disease: Another Arrow in the Quiver?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 608-610.	5.6	2
3	Commercial Sexual Exploitation During Adolescence: A US-Based National Study of Adolescent to Adult Health. Public Health Reports, 2022, 137, 53S-62S.	2.5	9
4	Methotrexate and rheumatoid arthritis associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2000337.	6.7	114
5	Essential Components of an Interstitial Lung Disease Clinic. Chest, 2021, 159, 1517-1530.	0.8	18
6	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.9	120
7	Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction. American Journal of Transplantation, 2021, 21, 2145-2160.	4.7	23
8	Chronic lung allograft dysfunction small airways reveal a lymphocytic inflammation gene signature. American Journal of Transplantation, 2021, 21, 362-371.	4.7	23
9	Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis. Histopathology, 2021, 79, 67-76.	2.9	25
10	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development., 2021, 222, 107798.		216
11	Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 295-310.	2.1	8
11	Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 295-310. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	5.6	41
	Medicine, 2021, 42, 295-310. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204,		
12	Medicine, 2021, 42, 295-310. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American	5.6	41
12	Medicine, 2021, 42, 295-310. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81. Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal,	5.6 5.6	107
12 13 14	Medicine, 2021, 42, 295-310. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81. Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2002533.	5.6 5.6 6.7	41 107 33
12 13 14	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81. Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2002533. Reflux-Aspiration in Chronic Lung Disease. Annals of the American Thoracic Society, 2020, 17, 155-164. CX3CR1–fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases.	5.6 5.6 6.7	41 107 33 39

#	Article	IF	CITATIONS
19	Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. American Journal of Medicine, 2019, 132, e854-e855.	1.5	1
20	Chronic Hypersensitivity Pneumonitis (CHP), an ILD with Distinct Molecular Signatures. , 2019, , .		0
21	Urine Proteomics Identifies Novel Biomarkers of IPF Disease Progression and Resolution. , 2019, , .		0
22	Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 2019, 197, 709-713.	3.3	18
23	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5 . 6	90
24	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018.	2.6	21
25	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. European Respiratory Journal, 2019, 53, 1802182.	6.7	11
26	POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest, 2019, 155, 258-260.	0.8	5
27	Rebuttal From Drs Lee and Fischer. Chest, 2019, 155, 263-264.	0.8	0
28	Pulmonary Fibrosis and Pyoderma Gangrenosum: What's the Common Denominator?. , 2019, , .		0
29	New trajectories in the treatment of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 442-449.	2.6	16
30	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clinic Proceedings, 2019, 94, 309-325.	3.0	78
31	The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1377-1378.	5. 6	4
32	Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Related Outcome Measures, 2018, Volume 9, 321-328.	1.2	33
33	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. New England Journal of Medicine, 2018, 379, 2209-2219.	27.0	326
34	Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review. Current Pulmonology Reports, 2018, 7, 118-125.	1.3	46
35	The Lung in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1544-1554.	5.6	198
36	Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1527-1538.	5 . 6	127

#	Article	IF	Citations
37	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 850-858.	5.6	74
38	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine, the, 2018, 6, 707-714.	10.7	109
39	OP0284â€Muc5b promoter variant rs35705950 is a risk factor for rheumatoid arthritis – interstitial lung disease. , 2018, , .		0
40	MUC5B is expressed by bronchoalveolar epithelia and is associated with ER stress in idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease. , 2018, , .		0
41	Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis. , 2018, , .		0
42	Pathologic Findings and Prognosis in a LargeÂProspective Cohort of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 152, 502-509.	0.8	131
43	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	5.6	166
44	Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respiratory Medicine, 2017, 127, 1-6.	2.9	37
45	The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respiratory Medicine, 2017, 127, 51-56.	2.9	49
46	Mortality Risk Prediction in Scleroderma-Related Interstitial LungÂDisease. Chest, 2017, 152, 999-1007.	0.8	61
47	"An Ounce of Prevention ― Will This Be the Future for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1240-1241.	5.6	0
48	Personalized medicine in interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2017, 23, 231-236.	2.6	8
49	Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged. Respiratory Medicine, 2017, 132, 267.	2.9	9
50	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	6.7	66
51	Connective Tissue Disease-Associated Interstitial Lung Diseases: Unresolved Issues. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 468-476.	2.1	14
52	The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation. Annals of the American Thoracic Society, 2016, 13, 1026-1033.	3.2	45
53	Management of Myositis-Related Interstitial Lung Disease. Chest, 2016, 150, 1118-1128.	0.8	106
54	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respiratory Medicine, 2016, 119, 150-154.	2.9	111

#	Article	IF	Citations
55	A diagnostic model for chronic hypersensitivity pneumonitis. Thorax, 2016, 71, 951-954.	5.6	70
56	Underâ€recognised coâ€morbidities in idiopathic pulmonary fibrosis: A review. Respirology, 2016, 21, 995-1004.	2.3	8
57	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	5.6	1,006
58	Cost analysis of asthma maintenance medications in a veteran population. Annals of Allergy, Asthma and Immunology, 2016, 116, 165-166.	1.0	0
59	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	3.0	16
60	Clinical outcomes of lung transplant recipients with telomerase mutations. Journal of Heart and Lung Transplantation, 2015, 34, 1318-1324.	0.6	82
61	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	2.6	38
62	The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 1058-1062.	2.9	9
63	Aspiration-Related Pulmonary Syndromes. Chest, 2015, 147, 815-823.	0.8	123
64	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	6.7	803
65	Survival in interstitial pneumonia with features of autoimmune disease: A comparison of proposed criteria. Respiratory Medicine, 2015, 109, 1326-1331.	2.9	40
66	Idiopathic pulmonary fibrosis: continuing to make progress. Lancet Respiratory Medicine, the, 2015, 3, 921-923.	10.7	1
67	Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease. , 2015, , .		0
68	Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 985-994.	2.9	105
69	A Comparison of Health-Related Quality of Life in Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis. Chest, 2014, 145, 1333-1338.	0.8	42
70	Idiopathic Pulmonary Fibrosis: CT and Risk of Death. Radiology, 2014, 273, 570-579.	7.3	85
71	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respiratory Medicine, the, 2014, 2, 557-565.	10.7	225
72	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT. Lancet Respiratory Medicine, the, 2014, 2, e5.	10.7	8

#	Article	IF	Citations
73	Predictors of mortality in rheumatoid arthritisâ€related interstitial lung disease. Respirology, 2014, 19, 493-500.	2.3	142
74	Rheumatoid Arthritis–associated Interstitial Lung Disease: Radiologic Identification of Usual Interstitial Pneumonia Pattern. Radiology, 2014, 270, 583-588.	7.3	109
75	Predicting Survival Across Chronic Interstitial Lung Disease. Chest, 2014, 145, 723-728.	0.8	366
76	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.8	67
77	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. , 2014, , 349-362.		3
78	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 249-255.	2.9	84
79	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respiratory Medicine, the, 2013, 1, 369-376.	10.7	349
80	Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 2013, 42, 750-757.	6.7	238
81	Clinical Features and Outcomes in Combined Pulmonary Fibrosis and Emphysema in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 234-240.	0.8	239
82	A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2012, 156, 684.	3.9	918
83	Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax, 2012, 67, 407-411.	5.6	160
84	Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respiratory Research, 2012, 13, 105.	3.6	32
85	Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Journal, 2012, 39, 352-358.	6.7	211
86	Gastroesophageal Reflux Therapy Is Associated with Longer Survival in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1390-1394.	5.6	382
87	Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1698-1702.	5.6	230
88	Comprehensive care of the patient with idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 348-354.	2.6	72
89	Primum non nocere: Safety in clinical trials for IPF. Respirology, 2011, 16, 723-724.	2.3	2
90	Priming With Endotoxin Increases Acute Lung Injury in Mice by Enhancing the Severity of Lung Endothelial Injury. Anatomical Record, 2011, 294, 165-172.	1.4	10

#	Article	IF	CITATIONS
91	Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2010, 35, 1322-1328.	6.7	463
92	Insulin regulates alveolar epithelial function by inducing Na+/K+-ATPase translocation to the plasma membrane in a process mediated by the action of Akt. Journal of Cell Science, 2010, 123, 1343-1351.	2.0	27
93	Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?. American Journal of Medicine, 2010, 123, 304-311.	1.5	183
94	Â2 Adrenergic agonist therapy may enhance alveolar epithelial repair in patients with acute lung injury. Thorax, 2008, 63, 189-190.	5 . 6	3